#Padcev
Big bladder cancer news: on Nov 13, the FDA approved Imfinzi + Padcev around surgery — drugs before bladder removal, then Imfinzi alone after — for muscle-invasive bladder cancer. 🧵
November 16, 2026 at 12:00 PM
How it works, in plain terms: Padcev is a targeted drug that delivers chemo straight to cancer cells. Imfinzi is immunotherapy — it helps the immune system spot and attack cancer. Used together before surgery.
November 16, 2026 at 12:00 PM
2
In February 2026 he started:
Ivermectin
Fenbendazole
Apricot Seeds
Soursop
Oncologist: Keytruda, Padcev

Report after 4 months: Remission.

Hundreds of bladder cancer patients have gone from Stage 4 to No Evidence of Disease typically after 3-6 months of
November 13, 2026 at 4:10 PM
EC expands Padcev + Keytruda approval to adults with resectable muscle-invasive bladder cancer regardless of cisplatin eligibility

https://cancerletter.com/drugs-and-targets/20261030_9d/
EC expands Padcev + Keytruda approval to adults with resectable muscle-invasive bladder cancer regardless of cisplatin eligibility - The Cancer Letter
The European Commission has granted Marketing Authorization for Padcev (enfortumab vedotin), in combination with Keytrud
cancerletter.com
November 6, 2026 at 1:00 PM
Patients with #muscleinvasivebladdercancer in England and Wales can now receive #NHS treatment with a regimen of MSD's #Keytruda and Astellas' #Padcev – before and after surgery – to prevent or delay the disease from coming back.

pharmaphorum.com/news/nice-ba...
NICE backs Keytruda/Padcev combo for bladder cancer
Patients with muscle-invasive bladder cancer can now receive NHS treatment with MSD's Keytruda and Astellas' Padcev, given before and after surgery.
pharmaphorum.com
November 5, 2026 at 11:33 AM
#PFE Q3 2026

EPS +0.0% YoY

• Justerad EPS och omsättningsguide höjs för helåret 2026
• Operationell tillväxt på 32% för lanserade och förvärvade produkter
• Stark utveckling inom Eliquis och Padcev

https://tickertapenews.io/artikel/?id=13189
November 3, 2026 at 1:12 PM
アステラス製薬は4日、27年3月期の連結純利益予想(国際会計基準)を前年比20.1%増の3500億円に上方修正した。抗がん剤のPADCEV(パドセブ)やミラベグロンが好調に進捗したほか、為替の影響を織り込んだ。IBESがまとめたアナリスト12人の予想平均値3727億円は下回った。従来予想は3000億円だった。 reut.rs/48hfOXX
アステラス、通期純利益予想を上方修正 市場予想は下回る
アステラス​製薬は4日、27年3月期の連結純利益‌予想(国際会計基準)を前​年比20.1%増の3500億円に​上方修正した。抗⁠がん剤のPADCEV(パ​ドセブ)やミ​ラベグロンが好調に進捗したほか、為替​の影響を​織り込んだ。IBESがまとめたア‌ナリ⁠スト12人の予想平均値3727億円は下回った。従来予​想は3000億円だっ​た。
reut.rs
November 4, 2026 at 10:30 AM
アステラス製薬は4日、27年3月期の連結純利益予想(国際会計基準)を前年比20.1%増の3500億円に上方修正した。抗がん剤のPADCEV(パドセブ)やミラベグロンが好調に進捗したほか、為替の影響を織り込んだ。IBESがまとめたアナリスト12人の予想平均値3727億円は下回った。従来予想は3000億円だった。 reut.rs/4iyh7X3
アステラス、通期純利益予想を上方修正 市場予想は下回る
アステラス​製薬は4日、27年3月期の連結純利益‌予想(国際会計基準)を前​年比20.1%増の3500億円に​上方修正した。抗⁠がん剤のPADCEV(パ​ドセブ)やミ​ラベグロンが好調に進捗したほか、為替​の影響を​織り込んだ。IBESがまとめたア‌ナリ⁠スト12人の予想平均値3727億円は下回った。従来予​想は3000億円だっ​た。
reut.rs
November 4, 2026 at 8:21 AM
💊 #pharma

🇺🇸 #$PFE Pfizer Q3 revenue $16,583m, −0.4%. COVID −$1,119m. Eliquis in the US +$516m (+40%). Pfizer cites higher US net price (lower rebates) and global demand.

Adjusted EPS $0.87, flat; reported $0.56, −9%. 2026 revenue guidance raised to $62-64bn.

midgardfinance.com/companies/PFE/
November 3, 2026 at 1:00 PM
A #perioperative regimen for muscle-invasive #bladdercancer (MIBC) based on AstraZeneca's Imfinzi and Astellas/Pfizer's Padcev has improved survival in the #VOLGAstudy, but the jury is out on whether it will displace a rival, established alternative.

pharmaphorum.com/news/esmo26-...
October 25, 2026 at 6:25 PM
Merck, Pfizer, and Astellas also released Signatera ctDNA data for their perioperative bladder cancer trial.
AstraZeneca Gathers Data on Imfinzi, Padcev in Adjuvant, Neoadjuvant Bladder Cancer Using Signatera
AstraZeneca Gathers Data on Imfinzi, Padcev in Adjuvant, Neoadjuvant Bladder Cancer Using Signatera
ebx.sh
October 25, 2026 at 3:28 AM
Imfinzi-Padcev duo lowers bladder cancer mortality risk by 42% #$AZN #$PFE #$ALPMY #ESMO2026 firstwordpharma.com/story/8264413
October 25, 2026 at 2:26 AM
October 24, 2026 at 1:20 AM
🏥 San Carlos prorroga sensores y Ravulizumab, Ramón y Cajal adjudica PADCEV y deja desierta su digitalización 💊📉

https://boesinpaja.es/article/san-carlos-prorroga-sensores-y-ravulizumab-ramon-y-cajal-adjudica-padcev-y-deja-desierta-su-digitalizacion-2133857

#Madrid
October 18, 2026 at 12:05 PM
2x Padcev + 1x Keytruda..that would be $90.000 sir and you’ll need it for a full year = $1.500.000
October 14, 2026 at 1:10 PM
Astellas previewed 21 ESMO 2026 abstracts on Padcev, Vyloy, Xtandi and setidegrasib. The release lists titles and time slots but no efficacy or safety figures.

#Oncology #Biotech #Medicine

Disclaimer: This is NOT a financial advice
October 12, 2026 at 2:40 AM
Nezgodno zavarovanje otrok pokriva stroške zdravljenja in rehabilitacije po poškodbah, kot so padci, udarci in opekline. V nasvetu prikazujemo najpogostejše vzroke poškodb in kako zavarovanje pomaga pri stroških. http://my.generali.social/Qjx6hqfCakAv
Od padcev in ran do izplačila zavarovalnine v infografiki
my.generali.social
October 6, 2026 at 6:25 AM
Zdravo! 👋

Zakaj imamo radi zgodbe o vzponu, padcu in ponovnem vzponu bolj kot tiste zgodbe, kjer ni nič padcev? Ker imamo raje emocije, ker smo bolj Homo Emoticus kot Homo Sapiens.

Tudi o Budimpešti, Trbovljah, Črnomlju in Ptuju. :)

opravicujemo.se/332/
Trnova pot herojev 🦸
Zdravo. Tokrat začnemo z ugotovitvijo, da imajo ljudje najraje zgodbe, kjer junak začne na dnu, se povzpne, pade in se spet pobere in na koncu zmaga v velikem triumfu. Zato bi morali zamenjati ime naš...
opravicujemo.se
October 5, 2026 at 8:54 AM
My operation was on my 66th bday. I have a double nephrostomy(not from bladder cancer, but from undiagnosed high blood pressure killed off my kidneys) so I could only do immunotherapy: Padcev & Keytruda. My oncologist Dr. Saqib Abbasi at KU Cancer Center told me the best we could hope for was
September 27, 2026 at 8:55 PM
【イミフィンジとPADCEVの周術期、米で優先審査】
AstraZenecaなどのVOLGA(695例)。シスプラチン化学療法が適応外、または希望しない筋層浸潤膀胱がん。周術期のデュルバルマブと術前エンホルツマブ ベドチンで、無イベント生存と全生存が有意に延びた。FDA優先審査。PDUFAは2026年第4四半期。承認そのものではない。
Imfinzi+EVの周術期併用療法、米国で優先審査指定──VOLGA第3相で無イベント生存・全生存を有意に改善
stellanews.life/technology/1...
Imfinzi+EVの周術期併用療法、米国で優先審査指定──VOLGA第3相で無イベント生存・全生存を有意に改善
AstraZeneca社は、durvalumab(Imfinzi)とenfortumab vedotin併用による周術期治療の適応追加申請が、筋層浸潤性膀胱がん患者を対象に米国FDAで優先審査に指定されたと発表した。VOLGA第3相試験の中間解析で無イベント生存期間と全生存期間の有意な改善が示されたことが根拠となっている。
stellanews.life
September 28, 2026 at 4:11 AM
glede vprašanja KaJ pA sPlOh LaHkO gLeDaMo Na TvS, lahko recimo pogledate igorjev dokumentarec o tem, kako sta dva modela ob pomoči fabrike prikolic ratala prva slovenska kompetitivna solo oceanska jadralca. ažo danes fura first linijo performance bark za beneteau. 365.rtvslo.si/arhiv/dokume...
September 25, 2026 at 4:50 PM